不同剂量卡格列净联合二甲双胍治疗2型糖尿病临床效果及炎症因子分析

Clinical Effect and Inflammatory Factors Analysis of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus

目的 2型糖尿病应用二甲双胍联合不同剂量卡格列净治疗效果分析。方法 选取临清市中医院2020年1月—2022年1月收治的90例2型糖尿病患者为研究对象,按随机数表法分为两组,对照组给予二甲双胍联合高剂量(300 mg)卡格列净,研究组给予二甲双胍联合低剂量(100 mg)卡格列净,分析两组血糖、炎症因子及安全性。结果 治疗后,两组血糖指标均显著降低,差异有统计学意义(P<0.05);研究组空腹血糖(5.37±0.86)mmol/L、餐后2 h血糖(7.28±0.78)mmol/L及糖化血红蛋白(6.97±0.82)%与对照组比较,差异无统计学意义(P>0.05)。两组炎症因子均显著降低,差异有统计学意义(P<0.05)。研究组IL-6(6.13±1.25)pg/mL、CRP(3.98±0.56)mg/L等炎症因子与对照组(6.06±1.31)pg/mL、(4.05±0.62)mg/L比较,差异无统计学意义(P>0.05)。研究组发生胃肠道反应、低血糖等不良反应发生率4.44%低于对照组的17.78%,差异有统计学意义(P<0.05)。结论 2型糖尿病应用二甲双胍联合不同剂量卡格列净治疗,均能有效改善血糖指标,降低炎症因子,且低剂量卡格列净更具用药安全性。

Objective To analyze the effect of metformin combined with different doses canagliflozin in the treatment of type 2 diabetes mellitus.Methods The data of 90 patients with type 2 diabetes admitted to Linqing Hospital of Traditional Chinese Medicine from January 2020 to January 2022 were selected.as the research subjets According to the random number table,the patients were divided into two groups,the control group was given metformin combined with high-dose(300 mg)canagliflozin,and the study group was given metformin combined with low-dose(100 mg)canagliflozin.The blood glucose,inflammatory factors and safety of the two groups were analyzed.Results After treatment,blood glucose indexes in both groups were significantly decreased,and the difference was statistically significant(P<0.05).Compared with the control group,the fasting blood glucose(5.37±0.86)mmol/L,the 2 h postprandial blood glucose(7.28±0.78)mmol/L and the glycosylated hemoglobin(6.97±0.82)%of the study group had no statistical significance(P>0.05).Inflammatory factors were significantly decreased in both groups,and the difference was statistically significant(P<0.05).Compared with the control group(6.06±1.31)pg/mL and(4.05±0.62)mg/L,the inflammatory factors such as IL-6(6.13±1.25)pg/mL and CRP(3.98±0.56)mg/L of the study group were no significal difference(P>0.05).The incidence of adverse reactions such as gastrointestinal reactions and hypoglycemia in the study group was 4.44%lower than 17.78%in the control group,and the difference was statistically significant(P<0.05).Conclusion Metformin combined with different doses canagliflozin in the treatment of type 2 diabetes can effectively improve blood glucoseindexes and reduce inflammatory factors, and low-dose canagliflozin is more safe.